Introduction and Rationale
Peritoneal dissemination of intra-abdominal malignancies has historically been viewed as a terminal condition with limited palliative options. The “peritoneal plasma barrier” significantly limits the penetration of systemic intravenous chemotherapy into peritoneal nodules, often resulting in sub-therapeutic local drug concentrations.
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) represents a paradigm shift in treating selected peritoneal surface malignancies (PSM). It is a locoregional therapy integrated into a two-step surgical procedure:
- Cytoreductive Surgery (CRS): The macroscopic removal of all visible tumor burden.
- HIPEC: The subsequent administration of heated chemotherapy directly into the abdominal cavity to eradicate microscopic residual disease.
The rationale for HIPEC is twofold:
- Pharmacokinetic Advantage: Intraperitoneal delivery allows for high local drug concentrations relative to systemic plasma levels, maximizing cytotoxicity in the peritoneal compartment while minimizing systemic toxicity. This is often quantified by the area under the curve (AUC) ratio of peritoneal-to-plasma concentration.
- Hyperthermic Synergy: Heat (typically 41°C–43°C) has direct cytotoxic effects, increases drug penetration into tissues (up to 2-3 mm), impairs DNA repair mechanisms in cancer cells, and synergizes with specific chemotherapeutic agents (notably platinum-based drugs and mitomycin C).
Key Prognostic Indices: PCI and CC Score
Success in CRS/HIPEC is predicated upon two standardized scoring systems utilized globally to assess disease extent and surgical success.
A. Peritoneal Cancer Index (PCI)
Developed by Sugarbaker, the PCI is an essential quantitative assessment of tumor load.
- The abdomen is divided into 13 regions (0–12).
- Lesion size in each region is scored: 0 (no tumor), 1 (5 cm).
- Maximum score: 39.
- Clinical Significance: High PCI scores correlate strongly with poor survival and increased morbidity. PCI thresholds for offering HIPEC vary by pathology (e.g., often <20 for colorectal, stricter for gastric).
B. Completeness of Cytoreduction (CC) Score
The CC score measures residual disease after surgical resection and before HIPEC instillation. It is the single most important prognostic factor controlled by the surgeon.
- CC-0: No macroscopic residual disease (the goal of CRS).
- CC-1: Residual nodules <2.5 mm.
- CC-2: Residual nodules 2.5 mm to 2.5 cm.
- CC-3: Residual nodules >2.5 cm.
- Clinical Significance: Long-term survival benefits are generally restricted to patients achieving CC-0 or CC-1.
Indications and Patient Selection
Patient selection is critical. HIPEC is a high-morbidity procedure reserved for patients with good performance status (typically ECOG 0-1), absent or limited extra-abdominal metastasis, and resectable peritoneal disease.
Primary Indications (Standard of Care)
- Pseudomyxoma Peritonei (PMP) / Appendiceal Neoplasms: CRS/HIPEC is the gold standard for low-grade and high-grade mucinous neoplasms of the appendix that have breached the appendix. Survival outcomes are significantly superior to systemic therapy alone.
- Diffuse Malignant Peritoneal Mesothelioma (DMPM): For select epithelioid subtypes, CRS/HIPEC offers the best chance for prolonged survival compared to systemic chemotherapy or palliative surgery.
Investigational Indications
- Gastric Cancer with Peritoneal Metastasis: Highly prevalent in Asia. Trials suggest benefit in highly selected patients with limited peritoneal disease (low PCI) or as prophylactic treatment in high-risk T4 tumors (GASTRICHIP trial underway).
- Sarcomatosis and Rare Tumors: Used in specialized centers on a case-by-case basis.
Secondary Indications (Evidence-Based but Evolving)
- Colorectal Carcinoma (CRC) with Peritoneal Metastasis:
- Indicated for limited peritoneal disease (low PCI) where complete cytoreduction is feasible.
- Evidence Nuance: The landmark randomized Dutch trial (Verwaal et al., 2003) established CRS+HIPEC over systemic therapy. However, the recent PRODIGE 7 trial questioned the added benefit of oxaliplatin-based HIPEC specifically after complete CRS in CRC patients, though critics argue the trial had design limitations. Mitomycin C remains a common agent.
- Epithelial Ovarian Cancer (EOC):
- Interval Setting: The phase III OVHIPEC-1 trial demonstrated a significant progression-free and overall survival benefit when adding cisplatin-based HIPEC to interval cytoreductive surgery for stage III ovarian cancer after neoadjuvant chemotherapy.
- Primary and Recurrent Settings: Investigational, with ongoing trials defining its role.
The Procedure: Technical Aspects
Symptoms often remain occult until the disease is advanced due to
the distensibility of the esophageal wall.
A. Cytoreductive Surgery (CRS)
This is often a lengthy and complex procedure involving multi-organ resections (colectomy, gastrectomy, hysterectomy, splenectomy) and peritonectomy procedures (stripping the parietal peritoneum from the diaphragm, pelvis, and paracolic gutters) to achieve a CC-0 score.
B. HIPEC Administration
Once CRS is complete, catheters are placed for inflow (heated perfusate) and outflow (drainage to the pump). Temperature probes monitor inflow, outflow, and intra-abdominal temperatures.
- Duration: Typically 30 to 90 minutes, depending on the protocol and drug.
- Techniques:
- Open (Coliseum Technique): The skin edges are suspended to a retractor frame, and a vapor barrier is applied. Allows manual manipulation of viscera to ensure uniform heat/drug distribution but poses a theoretical risk of aerosolized chemotherapy exposure to staff.
- Closed Technique: The abdomen is temporarily closed before perfusion. Reduces staff exposure and maintains heat well but may result in uneven drug distribution due to pooling.
C. Common Chemotherapeutic Agents
Selection depends on tumor histology and institutional protocol.
- Mitomycin C (MMC): Large molecular weight limits systemic absorption. Synergistic with heat. Standard for colorectal and appendiceal neoplasms.
- Platinum Agents (Cisplatin, Carboplatin, Oxaliplatin): Highly synergistic with heat. Standard for ovarian and gastric cancers; sometimes used for CRC and mesothelioma.
- Doxorubicin: Often used for mesothelioma or sarcomatosis.
Perioperative Management and Complications
CRS/HIPEC is associated with significant physiological stress, often described as a controlled systemic inflammatory response syndrome (SIRS) or “cytokine storm,” particularly during the hyperthermic phase.
- Morbidity and Mortality: Major morbidity (Clavien-Dindo grade III/IV) occurs in 20-40% of patients, with perioperative mortality ranging from 1-5% in high-volume centers.
Key Complications and Management Focus:
- Anastomotic Leak: The most feared surgical complication. The impact of heated chemotherapy on healing bowel anastomoses is a major concern; many surgeons opt for temporary diversion (ostomies), especially for low rectal anastomoses.
- Nephrotoxicity: High risk due to cisplatin use, fluid shifts, and potential rhabdomyolysis. Requires vigorous hydration and forced diuresis protocol during HIPEC.
- Hematologic Toxicity (Bone Marrow Suppression): Common with Mitomycin C, peaking 10-14 days post-op.
- Fluid and Electrolyte Shifts: The large peritoneal surface area absorbs fluid during perfusion, leading to edema, hypoalbuminemia, and electrolyte disturbances requiring careful intensive care monitoring.
- Prolonged Ileus: Almost universal due to extensive bowel manipulation and intraperitoneal chemotherapy.
Future Directions
The field is moving toward more personalized approaches and less invasive delivery methods.
- PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy): A laparoscopic technique administering chemotherapy as an aerosol under pressure. It enhances tissue penetration without the physiological stress of HIPEC. Currently used primarily in palliative settings or neoadjuvant trials for unresectable disease to downstage PCI.
- Prophylactic HIPEC: Investigating the use of HIPEC in high-risk colorectal or gastric cancer patients with no visible peritoneal metastasis but high risk of recurrence (e.g., T4 tumors, perforated tumors).
- Immunotherapy Combinations: Trials are exploring combining intraperitoneal chemotherapy with immune checkpoint inhibitors to stimulate a local anti-tumor immune response.
Conclusion
HIPEC, combined with complete cytoreductive surgery, is a powerful tool in the oncologic armamentarium for highly selected patients with peritoneal surface malignancies.
It has transformed certain diagnoses from fatal conditions to manageable chronic diseases with potential for cure.
However, its success is heavily dependent on patient selection, tumor biology, and the experience of the surgical and multidisciplinary team.
Disclaimer
This guide is intended for medical professionals and is based on evidence available up to early 2024.
Clinical protocols and indications vary by institution and evolving trial data.